Sab bio reports full year 2024 operating and financial results

Miami, march 31, 2025 (globe newswire) -- sab bio (nasdaq: sabs), (“sab bio” or the “company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (higg) for delaying the onset or progression of type 1 diabetes (t1d), today announced financial results for the fourth quarter of 2024 in addition to its full year financial results for the fiscal year ended december 31, 2024, and reported on recent accomplishments and anticipated milestones. samuel j. reich, chairman and ceo of sab bio stated, “our recent announcement of positive topline data for sab-142, further strengthens our belief that sab-142 has the potential to be the best in-class disease-modifying therapy for t1d.
SABS Ratings Summary
SABS Quant Ranking